09:51 AM EST - Fennec Pharmaceuticals Inc. : Announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing and granted Priority Review for the company’s New Drug Application (NDA) for PEDMARK™ (a unique formulation of sodium thiosulfate). PEDMARK is an investigational drug for the prevention of ototoxicity induced by cisplatin chemotherapy in patients one month to <18 years of age with localized, non-metastatic, solid tumors. Fennec Pharmaceuticals Inc.
shares T.FRX are trading unchanged at $9.00.
